Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta(®) in healthy subjects: A randomized, double‐blind trial

Lignende værker

• PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta(®)): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers
  af: Moosavi, Shahrzad, et al.
  Udgivet: (2020)
• Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects
  af: Hyland, Elizabeth, et al.
  Udgivet: (2016)
• Pharmacodynamics, safety, and immunogenicity of Pelmeg(®), a pegfilgrastim biosimilar in healthy subjects
  af: Wessels, Hendrik, et al.
  Udgivet: (2019)
• Initial testing of pegfilgrastim (Neulasta Onpro) on‐body injector in multiple radiological imaging environments
  af: Long, Zaiyang, et al.
  Udgivet: (2021)
• Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg(®), a pegfilgrastim biosimilar in healthy subjects
  af: Roth, Karsten, et al.
  Udgivet: (2019)